Krarup T, Rasmussen F, Gammelgaard P A
Scand J Urol Nephrol. 1978;12(1):11-5.
Thirteen patients with stage III or IV carcinoma of the prostate were treated with 2,6-cis-Diphenylhexamethylcyclotetrasiloxane (Cisobitan, a new organosilicon compound. The drug proved to be a strong antiandrogen and exerted all the known effects of estrogens, including feminization and cardiovascular complications. It is therefore doubtful whether Cisobitan will be a reasonable alternative to estrogens in the treatment of patients with advanced prostatic cancer.
13例Ⅲ期或Ⅳ期前列腺癌患者接受了2,6-顺式-二苯基六甲基环四硅氧烷（西索比坦，一种新型有机硅化合物）治疗。该药物被证明是一种强效抗雄激素药物，具有雌激素的所有已知作用，包括女性化和心血管并发症。因此，西索比坦在治疗晚期前列腺癌患者时是否会成为雌激素的合理替代药物值得怀疑。
